Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ordination Dr. Hommer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women aged over 18 years
Diagnosed primary open angle glaucoma treated with preserved prostaglandins for at least 6 months OR
Patients with ocular hypertension treated with preserved prostaglandins for at least 6 months
IOP ≤ 21 mmHg in the study eye at the screening examination (under treatment)
Mean TFT at the screening visit ≤ 6µm in the study eye
At least 2 symptoms of dry eye syndrome in the study eye (itching, stinging, blurred vision, foreign body sensation, debris, conjunctival redness) since at least one month
Tear break up time ≤ 10sec
You may not be if
Participation in a clinical trial in the 3 weeks before the screening visit
Severe visual field loss as defined as an MD of -15 or worse in the study eye
Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator
Sjögren's syndrome
Stevens-Johnson syndrome
Presence or history of a severe ocular condition that will interfere with the study aim as judged by the clinical investigator
Presence or history of allergic conjunctivitis
Treatment with corticosteroids in the 4 weeks preceding the study
Wearing of contact lenses
Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except glaucoma medication or topical lubricants
Ocular infection
Ocular surgery in the 6 months preceding the study (except laser trabeculoplasty)
Pregnancy, planned pregnancy or lactating
Contraindication against the use of topical prostaglandin therapy
Clareo Health | A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness
